Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up 14% year-to-date, the stock has outperformed benchmark indices in the sector, primarily driven by continued enthusiasm surrounding its pain program and the general view that there’s significant scarcity value with “multiple exciting pipeline assets in the backdrop of its uniquely profitable/durable CF franchise,” the analyst tells investors. Vertex’s Phase 2 study readout in lumbosacral radiculopathy is “the next test” and “a key binary event” coming in late-2024, the analyst added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex Pharmaceuticals upgraded to Buy from Hold at Jefferies
- Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
- CMS to work with Vertex, blubird to improve access to therapies, Reuters reports
- CRISPR Therapeutics (NASDAQ:CRSP) Boasts Solid Potential and Limited Risk
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
